Ovarian cancer has been shown to be a potential target for P2Y12 inhibitors. Ticagrelor, given by daily gavage, reduced the growth of primary tumors in rodent models of ovarian cancer (Cho et al., 2017). The drug caused a significant decrease in Ki67 immunostaining (a proliferation marker) in tumors resected form ticagrelor treated mice compared to controls. A direct role of P2Y12 in ovarian cancer cells was ruled out since Western blot analysis did not detect the receptor at the protein levels, and knocking down P2Y12 by siRNA or CRISPR-Cas9 techniques did not affect the cancer cell proliferation either in vitro or in vivo (Cho et al., 2017).